The great mismatch: Assessing cancer clinical trial accrual rates
Abstract
e23151
Background:
Efforts to increase cancer clinical trial accruals have been disappointing. Much focus has been placed on patient and some system barriers. Yet, pinpointing the causes of low accrual rates is needed to more effectively increase accruals. We undertook this study to identify the sites and breadth of low accrual rates to cancer clinical trials.
Methods:
At 3 participating Cancer Centers, we identified breast, liver and lung cancer patients at treatment decision points, when clinical trials would likely be more relevant. We included all open medical treatment trials for these cancers at these sites. Regular Expressions and Python algorithms identified patients with upcoming appointments to determine those at treatment decision points. Both trials and patients were classified by cancer type, stage, receptor and biomarker status. We then matched patients and trials and informed oncologists and patients about the match lists.
Results:
Of 63,255 patients with breast, liver or lung cancer and an appointment in the upcoming week, 11,502 were found to be at a treatment decision point (e.g., new, recurrent or progressing cancer) via SQL and 1552 via additional Python/RegEx algorithms. Of these,523 were consented and 326 matched to trials at a high level (e.g., type, stage, receptors). Subsequent manual review found 147 to be potentially eligible for an open trial. Of these, 39 enrolled in a CT. Among patients, 67% of breast, 11% of liver and 18% of lung, were early…
Read the paper
Related studies
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
- Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
- Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.